AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AstraZeneca PLCNYSE: AZN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $3.6B fell 1.8% year over year, behind the -0.3% change in trailing-twelve-month research & development. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- Research & development amounted to 24.2% of revenue in FY2025, down 0.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.8% toward the trailing-twelve-month pace of -0.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.23B USD
- Year-over-year change
- +4.8%
- 4-year CAGR
- +10.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.23B | +4.8% |
| FY2024 | 2024-12-31 | 13.58B | +24.2% |
| FY2023 | 2023-12-31 | 10.94B | +12.0% |
| FY2022 | 2022-12-31 | 9.76B | +0.3% |
| FY2021 | 2021-12-31 | 9.74B | — |
Research & Development vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.3% is the 9th highest of 10, against a peer median of +9.2%.
- Research & development amounts to 24.1% of revenue for AZN, versus a peer median of 18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 58.11B DKK | +28.3% | +29.3% | 17.6% | |
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $16.08B USD | +2.4% | +1.2% | 16.2% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $14.6B USD | +23.4% | +22.9% | 18.3% | |
| LTM Jun 2026 | $11.28B USD | +9.2% | +5.4% | 20.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | $10.72B USD | +3.1% | +1.5% | 21.8% | |
| LTM Sep 2026 | $9.96B USD | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| Peer median (excluding AZN) | — | +9.2% | +5.4% | 18.3% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.42B | 44.35B | 45.81B | 54.07B | 58.74B |
| Cost of Revenue | 12.44B | 12.39B | 8.27B | 10.21B | 10.63B |
| Gross Profit | 24.98B | 31.96B | 37.54B | 43.87B | 48.11B |
| Gross Margin | 66.8% | 72.1% | 82.0% | 81.1% | 81.9% |
| Research & Development | 9.74B | 9.76B | 10.94B | 13.58B | 14.23B |
| Selling, General & Admin | 15.59B | 17.98B | 18.22B | 20.22B | 20.51B |
| Operating Expenses | 23.92B | 28.2B | 29.35B | 33.86B | 34.36B |
| Depreciation & Amortization | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B |
| EBITDA | 5.11B | 9.09B | 13.42B | 15.44B | 19.83B |
| EBITDA Margin | 13.7% | 20.5% | 29.3% | 28.6% | 33.8% |
| Operating Income | 1.06B | 3.76B | 8.19B | 10B | 13.74B |
| Operating Margin | 2.8% | 8.5% | 17.9% | 18.5% | 23.4% |
| Interest Income | 43M | 81M | 301M | 345M | 360M |
| Interest Expense | 1.28B | 1.33B | 1.59B | 1.68B | 1.69B |
| Other Income / Expenses | (1.32B) | (1.26B) | (1.29B) | (1.31B) | (1.34B) |
| Income Before Tax | (265M) | 2.5B | 6.9B | 8.69B | 12.4B |
| Pre-Tax Margin | -0.7% | 5.6% | 15.1% | 16.1% | 21.1% |
| Income Tax Expense | (380M) | (792M) | 938M | 1.65B | 2.17B |
| Net Income | 112M | 3.29B | 5.96B | 7.04B | 10.26B |
| Net Margin | 0.3% | 7.4% | 13.0% | 13.0% | 17.5% |
| EPS (Basic) | 0.08 | 2.12 | 3.81 | 4.54 | 6.60 |
| EPS (Diluted) | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 |
| Weighted Avg Shares | 1.42B | 1.55B | 1.56B | 1.55B | 1.55B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.56B | 1.56B | 1.56B | 1.56B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.